New Delhi: Zydus Lifesciences reported a 29.6% jump in its net profit to Rs 1,024 crore for the October-December quarter of the current fiscal (Q3 FY25), as compared to Rs 790 crore posted in the year-ago period.
The company’s revenue from operations stood at Rs 5,269 crore, up 17% as compared to Rs 4,505 crore reported in Q3 FY24. Following the Q3 earnings announcement, Zydus Lifesciences Limited shares were trading 1.88% down at Rs 955.65 a piece on the NSE on February 5.
Zydus Lifesciences’ Managing Director Sharvil Patel commented: “We are pleased with the sustained growth momentum across our key businesses that has driven our Q3 performance. Our robust product portfolio execution in the US, market share gain in focused therapy segments and brands in India, and strategic leveraging of our global portfolio in International Markets position us well for future growth. We are on track to achieve our fiscal year 2025 goal of double-digit growth across our key businesses, coupled with improved profitability.”
“Looking ahead, we are strategically building growth levers to ensure sustained success, with patient centricity and quality at the core of our operations,” Patel added while sharing the future outlook.
In terms of biotech R&D, the company has completed Phase III clinical trials for one of the biosimilars. It has submitted an application to the DCGI seeking its permission to initiate Phase III clinical trials for one of the biosimilar antibody drug conjugates (ADC). On the novel biologics front, received permission from Review Committee on Genetic Manipulation (RCGM) to initiate pre-clinical studies for one of the ADCs. The company has completed Phase I clinical trials for Bivalent Typhoid Conjugate Vaccine (TCV).
In terms of specialty initiatives, the USFDA has accepted for filing and granted priority review to an NDA for CUTX101, a copper histidinate product candidate for treatment of Menkes disease.
Key highlights of – 9M FY25:
-
Revenue from operations at Rs. 167,136 mn, up 19% over last year.
-
Research & Development (R&D) investments stood at Rs. 13,756 mn (8.2% of revenues).
-
EBITDA was Rs. 49,330 mn, up 31% YoY. EBITDA margin stood at 29.5%, which is an improvement of 270 bps over the previous year.
-
Net Profit was Rs. 33,546 mn, up 25% YoY.
-
Capex (organic) for the nine months was Rs. 8,938 mn.
